跳转至内容
Merck
CN

1469005

USP

炔诺酮

United States Pharmacopeia (USP) Reference Standard

别名:

17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H26O2
化学文摘社编号:
分子量:
298.42
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
EC Number:
200-681-6
Beilstein/REAXYS Number:
1915671
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

炔诺酮, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

VIKNJXKGJWUCNN-XGXHKTLJSA-N

SMILES string

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

grade

pharmaceutical primary standard

API family

norethindrone

manufacturer/tradename

USP

mp

205-206 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... PGR(5241)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Norethindrone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Norethindrone Tablets
  • Norethindrone Acetate Tablets
  • Norethindrone and Mestranol Tablets
  • Norethindrone and Ethinyl Estradiol Tablets
  • Fluocinolone Acetonide Cream
  • Fluoxymesterone Tablets

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardEnvironment

signalword

Danger

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

涉药品监管产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

L R Wiseman et al.
Drugs & aging, 4(3), 238-256 (1994-03-01)
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. Transdermal administration avoids hepatic first-pass metabolism, allowing therapeutic
Rajesh Rajput et al.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 30(8), 680-683 (2008-09-13)
The association between the progestin-only pill used for treatment of menstrual disorders and central venous sinus thrombosis (CVST) has rarely been reported in the literature. This report describes a case of central venous sinus thrombosis following intake of norethindrone acetate
H F Taitel et al.
International journal of fertility and menopausal studies, 40(4), 207-223 (1995-07-01)
Norethindrone is utilized for numerous noncontraceptive therapies, especially during the menopause. Through an analysis of the literature we have described the pharmacological profile of norethindrone and the potential therapeutic implications of low-dose therapies, with an emphasis on endometrial pathology, climacteric
Kristof Chwalisz et al.
Reproductive sciences (Thousand Oaks, Calif.), 19(6), 563-571 (2012-03-30)
Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has
Bente Juel Riis et al.
American journal of obstetrics and gynecology, 187(4), 1101-1116 (2002-10-22)
This article is focused on the use of norethisterone acetate as progestogen in hormone replacement therapy. Emphasis is made on the fact that the primary reason for adding a progestogen to hormone replacement therapy is to protect the endometrium against

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持